(Adds further details on results from paragraph-2 onwards)
Aug 13 (Reuters) - Australia's CSL Ltd (CSL) reported a 15% jump in its full-year profit on Tuesday, on the back of strong growth in its core immunoglobulin business.
The biotech giant said its net profit after tax for the year ended June 30 was $3.01 billion, on a constant currency basis, higher than $2.86 billion from a year ago.
"Our largest franchise, the immunoglobulins portfolio, delivered exceptional growth driven by significant patient demand and the recovery in CSL Behring’s gross margin is progressing to plan," Chief Executive Officer Paul McKenzie said.
Total revenues for the full-year from Behring, company's largest and core immunoglobulin business division, came in 14% higher at $10.61 billion.
CSL proposed a final dividend of $1.45 per share, higher than $1.29 per share declared a year ago.
News: CSL UPDATE 1-Australia's CSL posts 15% jump in annual profit on strong immunoglobulin growth
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$257.38 |
Change
8.990(3.62%) |
Mkt cap ! $124.6B | |||
| Open | High | Low | Value | Volume |
| $252.00 | $258.31 | $251.10 | $370.9M | 1.440M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 90 | $257.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $257.38 | 3331 | 1 |
View Market Depth
| Last trade - 16.11pm 18/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |